Monday, February 20, 2006 8:55:27 PM
By John George
Philadelphia Business Journal
Updated: 7:00 p.m. ET Feb. 19, 2006
Pfizer Inc. is getting ready to launch what it hopes will be its next blockbuster: a new insulin product for diabetics that can be inhaled rather than injected.
Behind the scenes, two local companies played key roles in the development of Exubera, which just secured Food and Drug Administration approval.
Plexus Ventures in Maple Glen brokered the partnership of Nektar Therapeutics, which initially developed the drug, and Pfizer, which had the deep pockets needed to get the product through the regulatory approval process.
Meanwhile, a subsidiary of West Pharmaceutical Services in Lionville helped create, and will continue to make, the delivery system that will be used by patients taking the drug.
Exubera is a rapid-acting, dry-powder insulin designed to be inhaled into the lungs prior to each meal.
With more than 18 million people suffering from diabetes in the United States alone, many of whom have difficulty adhering to insulin shot regimens, industry analysts believe Exubera could quickly become a multibillion-dollar product for Pfizer.
In 1993, Plexus Ventures was retained by Nektar, then known as Inhale Therapeutic Systems, to assist the San Carlos, Calif., company's efforts to find a development and commercialization partner for its experimental inhaled insulin.
Plexus, founded in 1990 by a former SmithKline Beecham executive, is a life sciences consulting firm that specializes in helping pharmaceutical and biotechnology companies license drug candidates. Plexus was acquired by two other former SmithKline Beecham (now GlaxoSmithKline) executives, Robert P. Moran and Michael O'Sullivan, in 1993.
"It took a long time to get Exubera to market," said Moran, the firm's president. "Where the company had difficulty is its management, and I don't blame them for thinking this way, assumed the insulin companies would flock to the idea of an inhaled insulin product."
As it turned out, the three companies -- Eli Lilly, Novo Nordisk and Hoechst -- with the top selling insulin drugs in the market were all skeptical of an insulin formulation that required inhaling a powder into the lungs.
"We came up with the strategy of going after a respiratory treatment company since they already had knowledge about inhalation through their asthma medicines," Moran said.
Plexus also targeted pharmaceutical companies marketing orally administered anti-diabetic drugs other than insulin.
About 20 companies were identified as potential partners including Pfizer, which markets the oral anti-diabetic drug, Glucotrol, and was interested in extending its diabetes franchise into insulin.
After conducting thorough due diligence of Inhale's technologies, Pfizer -- best known for Lipitor and Viagra -- emerged as the top contender to license Nektar's insulin technologies. New York-based Pfizer signed a deal securing development and commercialization rights to the product in 1996.
Moran declined to disclose specific financial components of the deal, but he did say Pfizer has spent "hundreds of millions of dollars" getting the drug tested and approved.
"I give Pfizer a lot of credit," Moran said. "They were committed to this product and they stuck with it. Both companies showed a lot of commitment to each other. I think this is going to be an important product for Pfizer, whose pipeline is not as robust as it was a few years ago."
West Pharmaceutical also stands to benefit financially from Exubera through its subsidiary, The Tech Group, which it acquired last year for $140 million.
The Tech Group and West's device group merged into a single entity. It operates out of engineering and manufacturing facilities in Pennsylvania, Arizona, Indiana, Michigan, Puerto Rico, Ireland and Mexico.
The subsidiary specializes in injection molding components and devices.
Mike Treadaway, general manager of drug-delivery devices at Tech Group, said the company has been working with Nektar on an Exubera delivery device for seven years.
Treadaway said the device they created is about the size of a sunglasses case, weighs 4 ounces and is made primarily of plastic injection molding components.
Exubera will be sold in a blister pack. After a dose is loaded into the device the medicine is released. It appears as a cloud of insulin powder, resembling smoke, Treadaway explained, that is suspended in a chamber until inhaled by the patient.
"There is an enormous benefit to this delivery technique over the injection of insulin, which can be cumbersome," he said. "A lot of diabetic patients don't adhere to their treatment regimen. We are really hopeful the market will embrace this and it will revolutionize how people take insulin."
As one of two contract manufacturers of the delivery device, along with Bespak in England, West stands to benefit financially as well.
Treadaway said it's too early to estimate the potential revenue from the product for West, which last year generated sales of about $700 million. Last month the company said it expects revenue to grow by about 17.5 percent to between $810 million and $839 million.
"This [Exubera contract] does have an enormous potential for us," he said.
http://msnbc.msn.com/id/11454518/
Recent NKTR News
- Nektar Management to Present at Upcoming Investor Conferences • PR Newswire (US) • 09/03/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 01:15:41 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 01:15:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 01:14:28 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/19/2024 08:13:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/19/2024 08:03:19 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/19/2024 07:45:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:20:09 PM
- Nektar Therapeutics Reports Second Quarter 2024 Financial Results • PR Newswire (US) • 08/08/2024 08:15:00 PM
- Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets • PR Newswire (US) • 08/01/2024 10:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 10:02:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/14/2024 08:11:19 PM
- Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024 • PR Newswire (US) • 06/12/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 08:05:42 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 06/06/2024 04:15:16 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 06/05/2024 09:30:37 PM
- Nektar Management to Present at Upcoming Investor Conferences • PR Newswire (US) • 05/30/2024 10:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/28/2024 08:51:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 01:14:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 01:13:22 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 01:12:44 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/17/2024 08:25:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/17/2024 08:22:58 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/17/2024 08:14:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 08:36:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM